Newsbot

Costco (COST) Beats Q4 Earnings and Revenue Estimates

Costco (COST) delivered earnings and revenue surprises of +1.85% and +0.95%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?

Royal Caribbean Aktie: Neuer Sandals-Deal sorgt für Diskussionen

Toronto (www.aktiencheck.de) - Royal Caribbean-Aktienanalyse von BMO Capital Markets:Die erweiterte Partnerschaft von Royal Caribbean mit Sandals vergrößere das Angebot des Kreuzfahrtkonzerns an landbasierten Urlaubserlebnissen und erhöhe zugleich seinen Anteil an den gesamten Urlaubsausgaben der Reisenden. [mehr]

NANOBIOTIX Provides First Half 2026 Operational and Financial Update

PARIS and CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today provided an update on operational progress and reported financial results for the first six months of 2026.

Kevin Mahn: Market timing will cost you big

Mahn believes investors who wait for the “perfect dip” risk missing out on even bigger rebound days; he also recommends keeping cash on hand for opportunities that fit your goals.

Acuity Inc. Declares Quarterly Dividend

Atlanta, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Acuity Inc.?(NYSE: AYI) will pay a quarterly dividend of 20 cents per share. The dividend is payable on?November 2, 2026, to shareholders of record on October 16, 2026.

Barnes & Noble Education Announces Quarterly Cash Dividend

FLORHAM PARK, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Barnes & Noble Education, Inc. (NYSE: BNED) announced today that its board of directors declared a quarterly cash dividend of $0.08 per share of common stock payable to shareholders of record as of October 14, 2026. The dividend will be payable on October 29, 2026.

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026.